Current Report Filing (8-k)
24 March 2015 - 7:26AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 17, 2015
IGI LABORATORIES, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
|
001-08568 |
|
01-0355758 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
105 Lincoln Avenue
Buena, New Jersey |
|
08310 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (856) 697-1441
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
(d) Effective March 17, 2015, the Board of Directors
(the “Board”) of IGI Laboratories, Inc. (the “Company”) approved the appointment of John
Celentano to serve as a member of the Board. Mr. Celentano has also been appointed to serve as a member of the Company’s
audit committee of the Board.
There are no arrangements or understandings between Mr. Celentano
and any other person pursuant to which Mr. Celentano was appointed as a director. There are no transactions to which the Company
is a party and in which Mr. Celentano has a material interest that is required to be disclosed under Item 404(a) of Regulation
S-K.
Mr. Celentano will be compensated for his service on the Board
in accordance with the Company’s director compensation policy and will be reimbursed for reasonable expenses incurred in
connection with his service on the Board. In addition, the Company will enter into its standard form of director and officer indemnification
agreement with Mr. Celentano.
Item 8.01 Other Events.
The Company issued a press release in connection with the appointment
of Mr. Celentano to the Board. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit |
|
|
Number |
|
Description |
|
|
|
99.1 |
|
Press Release of IGI Laboratories, Inc. dated March 23, 2015. |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IGI LABORATORIES, INC. |
|
|
|
|
Date: March 23, 2015 |
By:
/s/ Jenniffer Collins |
|
Name: |
Jenniffer Collins |
|
Title: |
Chief Financial Officer |
Exhibit 99.1
News
From
Buena, NJ 08310
Release Date: March 23, 2015
Contact: |
Jenniffer Collins |
|
IGI Laboratories, Inc. |
|
(856) 697-4379 |
|
www.igilabs.com |
IGI LABORATORIES, INC. APPOINTS JOHN
CELENTANO TO BOARD OF DIRECTORS
BUENA, NJ – (PRNewswire) - IGI Laboratories, Inc.
(NYSE MKT: IG), a New Jersey-based specialty generic pharmaceutical company, today announced that it has appointed John Celentano
to its Board of Directors. Mr. Celentano will also serve on the Company’s Audit Committee.
Jason Grenfell-Gardner, President and CEO of the Company, commented, "We are thankful John has agreed
to join our Board of Directors. John’s extensive experience at Bristol-Myers Squibb, and his recent engagements as a consultant
to companies at various stages of growth in the pharmaceutical industry will be a great asset to IGI and its Board of Directors.”
Mr. Grenfell-Gardner continued, “We look forward to working with John, as we continue on our mission to be a leader in the
specialty generic prescription drug markets.”
Mr. Celentano currently works as an advisor to the
pharmaceutical industry. He has over 30 years of experience in the pharmaceutical industry, having held various senior
leadership positions at Bristol-Myers Squibb including: President, Bristol-Myers Squibb Healthcare Group (Mead Johnson
Nutrition, ConvaTec, and Medical Imaging) and Regional President roles in Emerging Markets/Asia Pacific, Latin America/Canada,
and UK/Northern Europe. He serves on the Boards of privately held JJ White Inc. and YourEncore Inc. He is Vice-Chairman
of CMMB, an international nonprofit healthcare organization. Mr. Celentano holds a B.A. from the University
of Delaware and a MBA from Drexel University.
About IGI Laboratories, Inc.
IGI Laboratories is a specialty generic
drug development and manufacturing company. Our mission is to be a leader in the specialty generic prescription drug market.
Forward-Looking Statements
This press release includes certain "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include,
but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that
are not historical facts and statements identified by words such as "plan," “believe," "continue",
“should” or words of similar meaning. Factors that could cause actual results to differ materially from these expectations
include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or
future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute
and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect
our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors;
and our inability to complete successfully future product acquisitions. These statements are based on our current beliefs or expectations
and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors"
in IGI Laboratories, Inc.’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports
we file with the Securities and Exchange Commission. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking
statements contained in this document as a result of new information, future events or otherwise, except as required by law.
Teligent (NASDAQ:TLGT)
Historical Stock Chart
From Apr 2024 to May 2024
Teligent (NASDAQ:TLGT)
Historical Stock Chart
From May 2023 to May 2024